6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Dated May 27, 2015

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant’s Name)

#1203-4464 Markham Street

Victoria, British Columbia

V8Z7X8

(250) 708-4272

(Address and telephone number of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ¨            Form 40-F  x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):  ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨             No  x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 27, 2015.

Aurinia Pharmaceuticals Inc.
By:	/s/ Michael R. Martin
	Name:	Michael R. Martin
	Title:	Chief Operating Officer

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	News Release – Aurinia Announces Results of Annual General Meeting
99.2	Report of Voting Results

3

EX-99.1

Exhibit 99.1

Aurinia Announces Results of Annual General Meeting

VICTORIA, British Columbia--(BUSINESS WIRE)--May 27, 2015--Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ:AUPH) (TSX:AUP) today announced the voting results from its annual general meeting (the “Meeting”) held on May 26, 2015.

A total of 24,371,491 shares were represented at the Meeting, being 75.54% of the Company’s issued and outstanding common shares. The shareholders voted on and approved all matters brought before the Meeting, including the election of the directors of the Company and the reappointment of PricewaterhouseCoopers LLP, Chartered Accountants as auditors of the Company.

Detailed results of the vote for the election of directors are provided below:

	Votes For				Votes Withheld
Nominee	#		%		#		%
Election of Directors
Richard Glickman		16,797,775		85.45		2,859,107		14.55
Stephen W. Zaruby		16,685,213		84.88		2,971,669		15.12
Benjamin Rovinski		19,655,289		99.99		1,593		0.01
Charles A. Rowland Jr.		19,655,369		99.99		1,513		0.01
David R.W. Jayne		19,655,338		99.99		1,544		0.01
Gregory M. Ayers		19,655,343		99.99		1,539		0.01
Hyuek Joon Lee		19,654,362		99.99		2,520		0.01

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best in class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

CONTACT:

Company Contact:

Stephen W. Zaruby, 250-708-4293

President & Chief Executive Officer

szaruby@auriniapharma.com

or

Investor & Media Contact:

Michael R. Martin, 250-708-4272

Chief Operating Officer

mmartin@auriniapharma.com

EX-99.2

Exhibit 99.2

AURINIA PHARMACEUTICALS INC.

Report of Voting Results

This report is filed pursuant to Section 11.3 of National Instrument 51-102 and relates to the results of voting at the annual general meeting of Aurinia Pharmaceuticals Inc. (the “Company”) held on May 26, 2015.

Description of Matter	Outcome of Vote
Resolution to elect the management nominees as directors of the Company.	All nominees proposed by management were elected to serve as directors of the Company until its next annual general meeting.
	Details of the voting by proxy are as follows:

Name	Votes in Favour	Votes Withheld
Richard Glickman	16,797,775 (85.45%)	2,859,107 (14.55%)
Stephen W. Zaruby	16,685,213 (84.88%)	2,971,669 (15.12%)
Benjamin Rovinski	19,655,289 (99.99%)	1,593 (0.01%)
Charles A. Rowland Jr.	19,655,369 (99.99%)	1,513 (0.01%)
David R.W. Jayne	19,655,338 (99.99)	1,544 (0.01%)
Gregory M. Ayers	19,655,343 (99.99%)	1,539 (0.01%)
Hyuek Joon Lee	19,654,362 (99.99%)	2,520 (0.01%)

Resolution to appoint PricewaterhouseCoopers LLP, Chartered Accountants as auditors of the Company until its next annual general meeting, at a remuneration to be fixed by the directors. Resolution passed by requisite majority.   Details of the voting by proxy are as follows:   Total shares voted in favour: 22,019,154 (97.45%)   Total shares withheld: 576,303 (2.55%)

DATED this 27th day of May, 2015

AURINIA PHARMACEUTICALS INC.
By:	Signed:	“Stephen W. Zaruby”
	Name:	Stephen Zaruby
	Title:	President and Chief Executive Officer